trial

Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients

NCTId NCT02298985
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 38 (actual)
Sponsored by Beersheva Mental Health Center
Primary completion 2017-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
38 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Triple
Start
2015-01
Primary completion
2017-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Curcumin

Sponsors

Beersheva Mental Health CenterLead Sponsor
Tirat Carmel Mental Health CenterCollaborator

Investigators

1
Prof. Vladimir Lerner, MD, PhDPrincipal Investigator

Sites

2 total
Beersheva, IsraelTirat Carmel, Israel

Facts & assertions

4 sourced
Enrollment
38
Phase
PHASE4
Primary Completion Date
2017-01
Status
COMPLETED
relationships
The graph out of here
drug
Curcumin
drug
lead_sponsor
Beersheva Mental Health Center
company
collaborator
Tirat Carmel Mental Health Center
company
indication
Schizophrenia
indication
Chronic Schizophrenia
indication
investigator
Prof. Vladimir Lerner, MD, PhD
person